David S. Miller

43.1k total citations · 8 hit papers
658 papers, 26.3k citations indexed

About

David S. Miller is a scholar working on Oncology, Obstetrics and Gynecology and Reproductive Medicine. According to data from OpenAlex, David S. Miller has authored 658 papers receiving a total of 26.3k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 143 papers in Obstetrics and Gynecology and 124 papers in Reproductive Medicine. Recurrent topics in David S. Miller's work include Endometrial and Cervical Cancer Treatments (127 papers), Ovarian cancer diagnosis and treatment (109 papers) and Drug Transport and Resistance Mechanisms (108 papers). David S. Miller is often cited by papers focused on Endometrial and Cervical Cancer Treatments (127 papers), Ovarian cancer diagnosis and treatment (109 papers) and Drug Transport and Resistance Mechanisms (108 papers). David S. Miller collaborates with scholars based in United States, United Kingdom and Canada. David S. Miller's co-authors include Björn Bauer, John B. Pritchard, Anika M. S. Hartz, Gert Fricker, Philip Payne, Samuel D. Wright, Barrie R. Cassileth, Edward J. Lusk, Lorraine L. Brown and Douglas H. Sweet and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David S. Miller

631 papers receiving 25.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

1994 632 citations David S. Miller et al. profile →
Soluble CD14 participates in the response of cells to lipopolysaccharide.

1992 591 citations David S. Miller et al. profile →
Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment

2015 517 citations David S. Miller et al. profile →
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

2004 479 citations David S. Miller et al. Journal of Clinical Oncology profile →
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019 377 citations Kathleen N. Moore, Angeles Alvarez Secord et al. profile →
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations

2017 322 citations David S. Miller et al. profile →
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

2019 289 citations Virginia L. Filiaci, Marcus E. Randall et al. profile →
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

2019 209 citations Marcus E. Randall, Virginia L. Filiaci et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David S. Miller

Since Specialization

Citations

This map shows the geographic impact of David S. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Miller more than expected).

Fields of papers citing papers by David S. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Miller. The network helps show where David S. Miller may publish in the future.

Co-authorship network of co-authors of David S. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Miller. A scholar is included among the top collaborators of David S. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Miller. David S. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial 2025 ·Clinical Cancer Research ·Jung‐Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, (unknown), Veena S. John, (unknown), Koji Matsuo, Jean Siedel, David S. Miller, (unknown), (unknown), John K. Chan, Leslie Bradford, Christopher B. Morse, Christa Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. Liu	1
2	737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study 2024 ·Annals of Oncology ·Anna Dańska-Bidzińska, (unknown), Vanda Salutari, Ali̇ Ayhan, Ignacio A. Romero, Tally Levy, (unknown), J.F. Baurain, Paweł Mach, (unknown), Helen Mackay, (unknown), (unknown), Brian M. Slomovitz, David S. Miller, Jodi A. McKenzie, Lan Yao, Vivek Khemka, Angélica Nogueira‐Rodrigues, Christian Marth	1
3	Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial 2024 ·Journal of Clinical Oncology ·Ann H. Klopp, Danielle Enserro, Matthew A. Powell, Marcus E. Randall, Julian C. Schink, Robert S. Mannel, Laura L. Holman, David Bender, (unknown), Floor Backes, Susan Zweizig, Steven Waggoner, Kristin Bradley, (unknown), Parviz Hanjani, Christopher J. Darus, William Small, Higinia R. Cárdenes, Jonathan Feddock, David S. Miller	10
4	Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment 2023 ·Cancers ·Ignace Vergote, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, David S. Miller	12
5	Seasonal Variation in Serum Testosterone Levels: Evidence from 2 Large Institutional Databases 2023 ·SHILAP Revista de lepidopterología ·David S. Miller, (unknown), (unknown), (unknown), (unknown), (unknown), Kathleen Hwang, Ranjith Ramasamy	0
6	2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma 2022 ·International Journal of Gynecological Cancer ·David S. Miller, Matthew L. Carlson, Jayanthi Lea, Zhe Li, (unknown), Judy Chen, Agustin A. García, Matthew Schlumbrecht, (unknown), Marilyn Huang	0
7	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial 2022 ·Journal of Clinical Oncology ·Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles Alvarez Secord, David G. Mutch, Alessandro D. Santin, David Warshal, Nick M. Spirtos, Paul DiSilvestro, Olga B. Ioffe, David S. Miller	47
8	2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 2022 ·International Journal of Gynecological Cancer ·Domenica Lorusso, Vicky Makker, Antonio Casado, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron‐Hay, Isabelle Ray‐Coquard, Ronnie Shapira‐Frommer, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva María Guerra Alia, Ulus Ali Şanlı, (unknown), Jodi A. McKenzie, (unknown), Nicoletta Colombo	1
9	Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer 2021 ·Cancer Epidemiology Biomarkers & Prevention ·Melissa A. Merritt, Howard D. Strickler, Alan D. Hutson, Mark H. Einstein, Thomas E. Rohan, Xiaonan Xue, Mark E. Sherman, Louise A. Brinton, Herbert Yu, David S. Miller, Nilsa C. Ramirez, Heather A. Lankes, Michael J. Birrer, Gloria S. Huang, Marc J. Gunter	10
10	Stage IVA cervical cancer: outcomes of disease related complications and treatment 2020 ·International Journal of Gynecological Cancer ·(unknown), (unknown), Matthew J. Carlson, David S. Miller, Jayanthi Lea	7
11	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer breakdown → 2019 ·Journal of Clinical Oncology ·Marcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae‐Weon Kim, Ritu Salani, Paul DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Y. Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol Aghajanian, David S. Miller	209
12	Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study 2011 ·Journal of Clinical Oncology ·Raymond Osborne, Virginia L. Filiaci, Julian C. Schink, Robert S. Mannel, Angeles Alvarez Secord, Joseph L. Kelley, Diane Provencher, David S. Miller, Allan Covens, Janice M. Lage	110
13	Epigenetic Repression of microRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer 2009 ·Cancer Research ·Yi-Wen Huang, Joseph C. Liu, Daniel E. Deatherage, Jingqin Luo, David G. Mutch, Paul J. Goodfellow, David S. Miller, Tim H-M. Huang	227
14	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo 2002 ·Journal of Clinical Investigation ·(unknown), Björn Bauer, David S. Miller, (unknown), (unknown), Thilo Spruß, Günther Bernhardt, (unknown), Lothar Färber, Harald Gschaidmeier, Armin Buschauer, Gert Fricker	25
15	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo 2002 ·Journal of Clinical Investigation ·(unknown), Björn Bauer, David S. Miller, (unknown), (unknown), Thilo Spruß, Günther Bernhardt, (unknown), Lothar Färber, Harald Gschaidmeier, Armin Buschauer, Gert Fricker	283
16	Knowledge, attitudes, and screening practices among older men regarding prostate cancer 2000 ·American Journal of Public Health ·C. Brooke Steele, David S. Miller, Christopher Maylahn, Robert J. Uhler, Christopher Baker	144
17	Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. 1999 ·PubMed ·Don Blackman, (unknown), David S. Miller	224
18	Role of TSG101 in Uterine Cervix Cancer 1999 ·Gynecologic Oncology ·John D. O’Boyle, (unknown), Kwun M. Fong, Wanrun Lin, David S. Miller, Carolyn Y. Muller	5
19	Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. 1997 ·PubMed ·David L. Tait, David S. Miller	4
20	Seasonal variations in food intake in two Ethiopian villages. 1972 ·PubMed ·David S. Miller, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact